IDH Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndrome

H&O  How common are isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)? ES  At diagnosis, approximately 20% to 25% […]

Alternatives to Intensive Treatment in Patients With AML

Abstract: A significant proportion of patients with acute myeloid leukemia (AML) are unable to tolerate standard induction chemotherapy regimens. This is particularly true for patients who […]

FLT3 Inhibitors in Acute Myeloid Leukemia: Increasing Options

H&O  What are the current treatments for acute myeloid leukemia (AML)? TK  In the past 5 years, the US Food and Drug Administration (FDA) has approved […]

Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia

H&O  What are the outcomes associated with hypomethylating agents in acute myeloid leukemia (AML)? CD  Decitabine and azacytidine, the hypomethylating agents typically used in this setting, […]

Evolving Strategies for the Management of Core-Binding Factor Acute Myeloid Leukemia

  H&O  What are core-binding factors? GB  Core-binding factors are heterodimeric transcription factors that are necessary at different stages of hematopoiesis. Core-binding factor alpha has 3 […]

Assessing the Risk of Heart Failure in Patients With Acute Leukemia 

  H&O  What is the risk of heart failure in patients with acute lymphoblastic leukemia or acute myeloid leukemia? MSC  Heart failure in patients with acute […]

New Drug Approvals in Acute Myeloid Leukemia: An Unprecedented Paradigm Shift

Abstract: We are witnessing an unprecedented paradigm shift in the treatment of acute myeloid leukemia (AML). For nearly 4 decades—since the introduction of cytarabine- and anthracycline-based […]

Midostaurin for Patients With Acute Myeloid Leukemia and FLT3 Mutations  

  H&O  What is the role of FLT3 in normal cells and acute myeloid leukemia? ML  FLT3 is a receptor tyrosine kinase. The name stands for […]

Treatment Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm 

  H&O  What is blastic plasmacytoid dendritic cell neoplasm (BPDCN)? NP  BPDCN is an aggressive cancer of the blood and bone marrow that presents clinically as […]

Hem/Onc News

Ivosidenib Approved for Relapsed or Refractory Acute Myeloid Leukemia On July 20, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Agios) for adults with […]

Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Mutations: Optimizing the Patient Experience

  H&O  What is the mechanism of action of enasidenib? GR Enasidenib (Idhifa, Celgene/Agios) is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) […]

Enasidenib for Patients With Relapsed Acute Myeloid Leukemia and the IDH2 Mutation

  H&O  Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]

A Mind Map for Managing Minimal Residual Disease in Acute Myeloid Leukemia

  Abstract: Advances in detecting traces of leukemia that were previously unidentifiable have increasingly led to the incorporation of information about residual disease into clinical decision […]

Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges

  Abstract: Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in […]

The Evolution of Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Myeloid Leukemia

  Abstract: Survival rates in subsets of pediatric patients who have acute myeloid leukemia (AML) with favorable risk features are now greater than 90%. However, outcomes […]

Guideline Recommendations for the Prophylaxis of Invasive Aspergillosis in AML

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Eunice S. Wang, MD Chief, Leukemia Service Professor of Oncology, Department of Medicine Roswell […]